Safety and Efficacy of Klotho and Follistatin Gene Therapy
Recruiting now · Early Phase 1 · Has a placebo group
Conditions studied: Healthy Adults
In brief
The purpose of this study is to investigate the safety and efficacy of a combination klotho and follistatin gene therapy, delivered via a nonviral plasmid in healthy adult volunteers. Additionally, this study seeks to understand the cognitive and health benefits of this gene therapy.
Key facts
- Study ID
- NCT07285629
- Run by
- Minicircle
- People needed
- 30
- Starts
- 2025-12-16
- Expected to finish
- 2026-06-01
- Last updated by the study team
- 2026-01-08
Who can join
Age: 50 and older, up to 80. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Adults aged 50 to 80 years
- General good health
- Willing to comply with all study-related procedures and visits
- Participant is open to morphological change
- If female, participant agrees to maintain contraception
- If female, participant agrees to take a pregnancy test
- If female, participant agrees to a pregnancy waiver
You may not qualify if…
- Currently enrolled in another clinical trial
- History of cancer, autoimmune disease, or chronic kidney/liver disease
- Use of immunosuppressive therapy
- Pregnant or breastfeeding
- Women of childbearing potential who are unwilling or unable to use effective contraception for the duration of the study.
- Regular use of NMDA (N-methyl-D-aspartate) antagonists (i.e., memantine, ketamine, etc.)
- Regular use of antiplatelet medications (i.e., aspirin)
- Any medical or psychiatric condition that could interfere with participation or pose safety concerns
- Unwilling or unable to provide informed consent
Where it is running
- Apeiron Center — Austin, Texas, United States (enrolling)
- Global Alliance of Regenerative Medicine (GARM) Clinic — Roatán, Bay Islands, Honduras
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.